{"protocolSection":{"identificationModule":{"nctId":"NCT02863328","orgStudyIdInfo":{"id":"NN9924-4223"},"secondaryIdInfos":[{"id":"2015-005209-36","type":"EUDRACT_NUMBER"},{"id":"U1111-1176-6006","type":"OTHER","domain":"World Health Organization (WHO)"},{"id":"2015","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2015"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus","officialTitle":"Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus","acronym":"PIONEER 2"},"statusModule":{"statusVerifiedDate":"2022-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-08-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-08-01","type":"ACTUAL"},"completionDateStruct":{"date":"2018-03-08","type":"ACTUAL"},"studyFirstSubmitDate":"2016-08-08","studyFirstSubmitQcDate":"2016-08-08","studyFirstPostDateStruct":{"date":"2016-08-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-10-15","resultsFirstSubmitQcDate":"2019-12-06","resultsFirstPostDateStruct":{"date":"2019-12-24","type":"ACTUAL"},"dispFirstSubmitDate":"2018-07-20","dispFirstSubmitQcDate":"2018-07-20","dispFirstPostDateStruct":{"date":"2018-07-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-07-11","lastUpdatePostDateStruct":{"date":"2022-07-20","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus."},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":822,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"14 mg oral semaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: semaglutide"]},{"label":"25 mg empagliflozin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: empagliflozin"]}],"interventions":[{"type":"DRUG","name":"semaglutide","description":"Oral administration once-daily.","armGroupLabels":["14 mg oral semaglutide"]},{"type":"DRUG","name":"empagliflozin","description":"Oral administration once-daily.","armGroupLabels":["25 mg empagliflozin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in HbA1c","description":"Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 26. The endpoint was evaluated based on data from the in-trial observation period which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication.","timeFrame":"Week 0, week 26"}],"secondaryOutcomes":[{"measure":"Change in Body Weight (Kg)","description":"Change from baseline (week 0) in body weight was evaluated at week 26. The endpoint was evaluated based on data from the in-trial observation period which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication.","timeFrame":"Week 0, week 26"},{"measure":"Change in HbA1c (%)","description":"Change from baseline (week 0) in HbA1c was evaluated at week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 52"},{"measure":"Change in Body Weight (kg)","description":"Change from baseline (week 0) in body weight was evaluated at week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 52"},{"measure":"Change in Fasting Plasma Glucose","description":"Change from baseline (week 0) in fasting plasma glucose was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26, week 52"},{"measure":"Change in SMPG : Mean of the 7-point Profile","description":"Change from baseline (week 0) in mean of the 7-point self-measured plasma glucose (SMPG) (i.e. before and after breakfast, lunch and dinner, and at bedtime) profile was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in SMPG : Mean Postprandial Increment Over All Meals","description":"Change from baseline (week 0) in mean postprandial glucose increment was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in Fasting C-peptide (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting C-peptide (Nanomoles per liter \\[nmol/L\\]) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in Fasting Insulin (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting insulin (picomoles per liter \\[pmol/L\\]) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in Fasting Pro-insulin (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting pro-insulin (pmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in Fasting Glucagon (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting glucagon (picograms per milliliter \\[pg/mL\\]) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in HOMA-IR (Ratio to Baseline)","description":"Change from baseline (week 0) in homeostatic model assessment index of insulin resistance (HOMA-IR) (%) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in HOMA-B (Ratio to Baseline)","description":"Change from baseline (week 0) in homeostatic model assessment index of beta-cell function (HOMA-B) (%) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in C-reactive Protein (Ratio to Baseline)","description":"Change from baseline (week 0) in C-reactive protein (milligrams per liter \\[mg/L\\]) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in Body Weight (%)","description":"Relative change from baseline (week 0) in body weight (kg) was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26, week 52"},{"measure":"Change in Body Mass Index","description":"Change from baseline (week 0) in body mass index (BMI) was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26, week 52"},{"measure":"Change in Waist Circumference","description":"Change from baseline (week 0) in waist circumference was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26, week 52"},{"measure":"Change in Fasting Total Cholesterol (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting total cholesterol (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in Fasting LDL Cholesterol (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting low density lipoprotein (LDL) cholesterol (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in Fasting HDL Cholesterol (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting high density lipoprotein (HDL) cholesterol (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in Fasting VLDL Cholesterol (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting very low density lipoprotein (VLDL) cholesterol (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in Fasting Free Fatty Acids (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting free fatty acids (FFA) (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. Because of an issue with the handling of the blood samples for FFA, all FFA data are considered invalid for this trial; thus, no conclusion with regards to FFA levels can be made based on the FFA data. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Change in Fasting Triglycerides (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting triglycerides (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26 and week 52"},{"measure":"Participants Who Achieve HbA1c <7.0 % (53 mmol/Mol) ADA Target (Yes/no)","description":"Participants who achieved HbA1c \\<7.0% (53 mmol/mol) (American Diabetes Association (ADA) target) at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 26 and week 52"},{"measure":"Participants Who Achieve HbA1c ≤6.5% (48 mmol/Mol), AACE Target (Yes/no)","description":"Participants who achieved HbA1c ≤6.5% (48 mmol/mol) (American Association of Clinical Endocrinologists (AACE) target) at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 26 and week 52"},{"measure":"Participants Who Achieve Weight Loss ≥5% (Yes/no)","description":"Participants who achieved weight loss of ≥5% at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 26 and week 52"},{"measure":"Participants Who Achieve Weight Loss ≥10% (Yes/no)","description":"Participants who achieved weight loss of ≥10% at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 26 and week 52"},{"measure":"Participants Who Achieve HbA1c <7.0 % (53 mmol/Mol) Without Hypoglycaemia (Severe or BG Confirmed Symptomatic Hypoglycaemia) and no Weight Gain (Yes/no)","description":"Participants who achieved HbA1c \\<7.0% (53 mmol/mol) without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia and without weight gain at week 26 and week 52. Severe or BG-confirmed symptomatic hypoglycaemia: an episode, that is severe according to the ADA classification or BG-confirmed by a plasma glucose value \\<3.1 mmol/L with symptoms consistent with hypoglycaemia. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 26 and week 52"},{"measure":"Participants Who Achieve HbA1c Reduction ≥1% (10.9 mmol/Mol) and Weight Loss ≥3% (Yes/no)","description":"Participants who achieved HbA1c reduction ≥1%-point and weight loss of ≥3% at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 26 and week 52"},{"measure":"Time to Additional Anti-diabetic Medication","description":"Presented results are the number of participants who had taken additional anti-diabetic medication anytime during the periods, from week 0 to week 26 and week 0 to week 52. Additional anti-diabetic medication: use of new anti-diabetic medication for more than 21 days with the initiation at or after randomisation (week 0) and before (planned) end-of-treatment (week 26/week 52), and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline) for more than 21 days with the intensification at or after randomisation and before (planned) end-of-treatment. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Weeks 0-52"},{"measure":"Time to Rescue Medication","description":"Presented results are the number of participants who had taken rescue medication anytime during the periods, from week 0 to week 26 and week 0 to week 52. Rescue medication: use of new antidiabetic medication as add-on to trial product and used for more than 21 days with the initiation at or after randomisation (week 0) and before last day on trial product, and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline for more than 21 days with the intensification at or after randomisation and before last day on trial product. Results are based on the data from the on-treatment without rescue medication observation period. On-treatment without rescue medication observation period: the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication.","timeFrame":"Weeks 0-52"},{"measure":"Number of Treatment-emergent Adverse Events (TEAE)","description":"A treatment-emergent adverse event (TEAE) is defined as an adverse event (AE) with onset in the on-treatment observation period (the time period where participants are considered treated with trial product) and was assessed up to approximately 57 weeks (52-week treatment period plus the 5-week follow-up period).","timeFrame":"Weeks 0-57"},{"measure":"Change in Amylase (Ratio to Baseline)","description":"Change from baseline (week 0) in amylase (units per liter \\[U/L\\]) at week 26 and week 52 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","timeFrame":"Week 0, week 26, week 52"},{"measure":"Change in Lipase (Ratio to Baseline)","description":"Change from baseline (week 0) in lipase (U/L) at week 26 and week 52 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","timeFrame":"Week 0, week 26, week 52"},{"measure":"Change in Pulse Rate","description":"Change from baseline (week 0) in pulse rate was evaluated at week 26 and week 52. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","timeFrame":"Week 0, week 26, week 52"},{"measure":"Change in Blood Pressure (Systolic and Diastolic Blood Pressure)","description":"Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated at week 26 and week 52. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","timeFrame":"Week 0, week 26, week 52"},{"measure":"Change in ECG","description":"Change from baseline (week 0) in electrocardiogram (ECG) was evaluated at week 26 and week 52. Change from baseline results are presented as shift in findings (normal, abnormal and not clinically significant (NCS), and abnormal and clinically significant (CS)) from week 0 to week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week 0, week 26, week 52"},{"measure":"Change in Physical Examination","description":"The physical examination findings (normal, abnormal NCS and abnormal CS) of the participants at week -2 and week 52 are presented for the following examinations: Cardiovascular system, Nervous system (central and peripheral); Gastrointestinal system, incl. mouth; General appearance; Head (ears, eyes, nose), throat, neck; Lymph node palpation; Musculoskeletal system; Respiratory system; Skin; Thyroid gland. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week -2, week 52"},{"measure":"Change in Eye Examination","description":"The eye examination findings (normal, abnormal NCS and abnormal CS) of the participants at baseline (week -2) and week 52 are presented. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Week -2, week 52"},{"measure":"Occurrence of Anti-semaglutide Binding Antibodies (Yes/no)","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. Number of participants who measured with anti-semaglutide binding antibodies anytime during post-baseline visits (week 0 to week 57) are presented. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Weeks 0-57"},{"measure":"Occurrence of Anti-semaglutide Neutralising Antibodies (Yes/no)","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. Number of participants who measured with anti-semaglutide neutralising antibodies anytime during post-baseline visits (week 0 to week 57) are presented. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Weeks 0-57"},{"measure":"Occurrence of Anti-semaglutide Binding Antibodies Cross Reacting With Native GLP-1 (Yes/no)","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. Number of participants who measured with anti-semaglutide binding antibodies cross reacting with native glucagon-like peptide-1 (GLP-1) anytime during post-baseline visits (week 0 to week 57) are presented. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Weeks 0-57"},{"measure":"Occurrence of Anti-semaglutide Neutralising Antibodies Cross Reacting With Native GLP-1 (Yes/no)","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. Number of participants who measured with anti-semaglutide neutralising antibodies cross reacting with native GLP-1 anytime during post-baseline visits (week 0 to week 57) are presented. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Weeks 0-57"},{"measure":"Anti-semaglutide Binding Antibody Levels","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. It is based on the data from participants who were measured with anti-semaglutide antibodies anytime during post-baseline visits (week 0 to week 57). Results are presented as percentage of bound radioactivity-labelled semaglutide /total added radioactivity-labelled semaglutide (%B/T). The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","timeFrame":"Weeks 0-57"},{"measure":"Number of Treatment-emergent Severe or Blood Glucose-confirmed Symptomatic Hypoglycaemic Episodes","description":"Treatment-emergent hypoglycaemia is an episode with onset in the on-treatment observation period (the time period where participants are considered treated with trial product) and was assessed up to approximately 57 weeks (52-week treatment period plus the 5-week follow-up period). Severe or BG-confirmed symptomatic hypoglycaemia is an episode that is severe according to the American Diabetes Association classification or blood glucose-confirmed by a plasma glucose value \\<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","timeFrame":"Weeks 0-57"},{"measure":"Participants With Treatment-emergent Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes (Yes/no)","description":"Number of participants with treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes was recorded during week 0-57. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","timeFrame":"Weeks 0-57"},{"measure":"Semaglutide Plasma Concentrations for Population PK Analyses","description":"Semaglutide plasma concentrations were measured after 25 minutes post-dose at week 4, 26 and 52. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","timeFrame":"Weeks 0-52"},{"measure":"SNAC Plasma Concentrations","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. Sodium N-\\[8-(2-hydroxybenzoyl) amino\\]caprylate (SNAC) plasma concentrations were measured after 25 and 40 minutes post-dose at week 4, 26 and 52. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","timeFrame":"Weeks 0-52"},{"measure":"Change in Short Form Health Survey Version 2.0 (SF-36v2™, Acute Version) Health Survey: Scores From the 8 Domains and Summaries of the Physical Component Score (PCS) and the Mental Component Score (MCS)","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The 0-100 scale scores (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively of the 2009 U.S. general population. Change from baseline (week 0) in the domain scores and component summary (PCS and MCS) scores were evaluated at weeks 26 and 52. A positive change score indicates an improvement since baseline. Results are based on the data from the in-trial observation period.","timeFrame":"Week 0, week 26, week 52"},{"measure":"Change in CoEQ: Scores From the 4 Domains and the 19 Items","description":"Change from baseline (week 0) in Control of Eating Questionnaire (CoEQ) was evaluated at weeks 26 and 52. The CoEQ comprised 19 items to assess the intensity and type of food cravings, as well as subjective sensation of appetite and mood, with the 4 domains: 'craving control' (items 9-12, 19), 'positive mood' (items 5-8), 'craving for savoury' (items 4, 16-18) and 'craving for sweet' (items 3, 13-15). The 19 items were scored on an 11-point graded response scale ranging from 10 to 0, with items relating to each of the 4 domains being averaged to create a final score. A low score in the domains 'craving for sweet and 'craving for savoury' represents a low level of craving; whereas a high score in the domains 'craving control' and 'positive mood' represents good control and a good mood, respectively. Results are based on the data from the in-trial observation period.","timeFrame":"Week 0, week 26, week 52"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial\n* Male or female, age above or equal to 18 years at the time of signing informed consent\n* Diagnosed with type 2 diabetes mellitus at least 90 days prior to day of screening\n* HbA1c (glycosylated haemoglobin) of 7.0-10.5 % (53-91 mmol/mol) (both inclusive)\n* Stable daily dose of metformin (at least 1500 mg or maximum tolerated dose as documented in the subject medical record) at least 90 days prior to the day of screening\n\nExclusion Criteria:\n\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice).For certain specific countries: Additional specific requirements apply\n* Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol\n* Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma\n* History of pancreatitis (acute or chronic)\n* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)\n* Any of the following: myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening\n* Subjects presently classified as being in New York Heart Association Class IV\n* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening\n* Subjects with ALT (alanine aminotransferase) above 2.5 x upper normal limit\n* Renal impairment defined as Estimated Glomerular Filtration Rate below 60 mL/min/1.73 m\\^2 as per Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI)\n* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening. An exception is short-term insulin treatment for acute illness for a total of below or equal to 14 days\n* Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within 90 days prior to randomisation\n* History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ)\n* History of diabetic ketoacidosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Global Clinical Registry (GCR, 1452)","affiliation":"Novo Nordisk A/S","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Novo Nordisk Investigational Site","city":"Tuscumbia","state":"Alabama","zip":"35674","country":"United States","geoPoint":{"lat":34.7312,"lon":-87.70253}},{"facility":"Novo Nordisk Investigational Site","city":"Encino","state":"California","zip":"91436","country":"United States","geoPoint":{"lat":34.15917,"lon":-118.50119}},{"facility":"Novo Nordisk Investigational Site","city":"La Mesa","state":"California","zip":"91942","country":"United States","geoPoint":{"lat":32.76783,"lon":-117.02308}},{"facility":"Novo Nordisk Investigational Site","city":"Northridge","state":"California","zip":"91325","country":"United States","geoPoint":{"lat":34.22834,"lon":-118.53675}},{"facility":"Novo Nordisk Investigational Site","city":"Palm Springs","state":"California","zip":"92262-6972","country":"United States","geoPoint":{"lat":33.8303,"lon":-116.54529}},{"facility":"Novo Nordisk Investigational Site","city":"Poway","state":"California","zip":"92064","country":"United States","geoPoint":{"lat":32.96282,"lon":-117.03586}},{"facility":"Novo Nordisk Investigational Site","city":"Riverside","state":"California","zip":"92506","country":"United States","geoPoint":{"lat":33.95335,"lon":-117.39616}},{"facility":"Novo Nordisk Investigational Site","city":"Spring Valley","state":"California","zip":"91978","country":"United States","geoPoint":{"lat":32.74477,"lon":-116.99892}},{"facility":"Novo Nordisk Investigational Site","city":"Bradenton","state":"Florida","zip":"34201","country":"United States","geoPoint":{"lat":27.49893,"lon":-82.57482}},{"facility":"Novo Nordisk Investigational Site","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Novo Nordisk Investigational Site","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Novo Nordisk Investigational Site","city":"Jacksonville","state":"Florida","zip":"32277","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Novo Nordisk Investigational Site","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Novo Nordisk Investigational Site","city":"Miami Lakes","state":"Florida","zip":"33014","country":"United States","geoPoint":{"lat":25.90871,"lon":-80.30866}},{"facility":"Novo Nordisk Investigational Site","city":"Orlando","state":"Florida","zip":"32801","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Novo Nordisk Investigational Site","city":"Oviedo","state":"Florida","zip":"32765","country":"United States","geoPoint":{"lat":28.67,"lon":-81.20812}},{"facility":"Novo Nordisk Investigational Site","city":"Atlanta","state":"Georgia","zip":"30328","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Novo Nordisk Investigational Site","city":"Perry","state":"Georgia","zip":"31069","country":"United States","geoPoint":{"lat":32.45821,"lon":-83.73157}},{"facility":"Novo Nordisk Investigational Site","city":"Meridian","state":"Idaho","zip":"83646","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"Novo Nordisk Investigational Site","city":"Peoria","state":"Illinois","zip":"61603","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Novo Nordisk Investigational Site","city":"Evansville","state":"Indiana","zip":"47713","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"Novo Nordisk Investigational Site","city":"Indianapolis","state":"Indiana","zip":"46254","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Novo Nordisk Investigational Site","city":"Lexington","state":"Kentucky","zip":"40502","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Novo Nordisk Investigational Site","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Novo Nordisk Investigational Site","city":"Baton Rouge","state":"Louisiana","zip":"70808-4124","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Novo Nordisk Investigational Site","city":"Rockville","state":"Maryland","zip":"20852","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Novo Nordisk Investigational Site","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Novo Nordisk Investigational Site","city":"Buckley","state":"Michigan","zip":"49620","country":"United States","geoPoint":{"lat":44.50445,"lon":-85.67701}},{"facility":"Novo Nordisk Investigational Site","city":"Kalamazoo","state":"Michigan","zip":"49009","country":"United States","geoPoint":{"lat":42.29171,"lon":-85.58723}},{"facility":"Novo Nordisk Investigational Site","city":"Butte","state":"Montana","zip":"59701","country":"United States","geoPoint":{"lat":46.00382,"lon":-112.53474}},{"facility":"Novo Nordisk Investigational Site","city":"Albany","state":"New York","zip":"12203","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"Novo Nordisk Investigational Site","city":"Northport","state":"New York","zip":"11768","country":"United States","geoPoint":{"lat":40.90093,"lon":-73.34317}},{"facility":"Novo Nordisk Investigational Site","city":"Wilmington","state":"North Carolina","zip":"28401","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"Novo Nordisk Investigational Site","city":"Cincinnati","state":"Ohio","zip":"45245","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Novo Nordisk Investigational Site","city":"Mason","state":"Ohio","zip":"45040-6815","country":"United States","geoPoint":{"lat":39.36006,"lon":-84.30994}},{"facility":"Novo Nordisk Investigational Site","city":"Philadelphia","state":"Pennsylvania","zip":"19140","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Novo Nordisk Investigational Site","city":"Greer","state":"South Carolina","zip":"29651","country":"United States","geoPoint":{"lat":34.93873,"lon":-82.22706}},{"facility":"Novo Nordisk Investigational Site","city":"Humboldt","state":"Tennessee","zip":"38343","country":"United States","geoPoint":{"lat":35.81979,"lon":-88.9159}},{"facility":"Novo Nordisk Investigational Site","city":"Kingsport","state":"Tennessee","zip":"37660","country":"United States","geoPoint":{"lat":36.54843,"lon":-82.56182}},{"facility":"Novo Nordisk Investigational Site","city":"Arlington","state":"Texas","zip":"76012-4637","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"facility":"Novo Nordisk Investigational Site","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Novo Nordisk Investigational Site","city":"Houston","state":"Texas","zip":"77004","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Novo Nordisk Investigational Site","city":"Houston","state":"Texas","zip":"77074","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Novo Nordisk Investigational Site","city":"Katy","state":"Texas","zip":"77450","country":"United States","geoPoint":{"lat":29.78579,"lon":-95.8244}},{"facility":"Novo Nordisk Investigational Site","city":"San Antonio","state":"Texas","zip":"78209","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Novo Nordisk Investigational Site","city":"San Antonio","state":"Texas","zip":"78228-3419","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Novo Nordisk Investigational Site","city":"San Antonio","state":"Texas","zip":"78258","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Novo Nordisk Investigational Site","city":"Richmond","state":"Virginia","zip":"23219","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Novo Nordisk Investigational Site","city":"CABA","zip":"C1417EYG","country":"Argentina"},{"facility":"Novo Nordisk Investigational Site","city":"Capital Federal","zip":"1405","country":"Argentina"},{"facility":"Novo Nordisk Investigational Site","city":"Córdoba","zip":"X5006IKK","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Novo Nordisk Investigational Site","city":"Córdoba","zip":"X5016KEH","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Novo Nordisk Investigational Site","city":"São Paulo","state":"São Paulo","zip":"01228-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Novo Nordisk Investigational Site","city":"Porto Alegre","zip":"90035-170","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Novo Nordisk Investigational Site","city":"São Paulo","zip":"05437-010","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Novo Nordisk Investigational Site","city":"Karlovac","zip":"47000","country":"Croatia","geoPoint":{"lat":45.49167,"lon":15.55}},{"facility":"Novo Nordisk Investigational Site","city":"Krapinske Toplice","zip":"49217","country":"Croatia","geoPoint":{"lat":46.09333,"lon":15.84333}},{"facility":"Novo Nordisk Investigational Site","city":"Pula","zip":"52100","country":"Croatia","geoPoint":{"lat":44.86833,"lon":13.84806}},{"facility":"Novo Nordisk Investigational Site","city":"Virovitica","zip":"33000","country":"Croatia","geoPoint":{"lat":45.83448,"lon":17.38555}},{"facility":"Novo Nordisk Investigational Site","city":"Zagreb","zip":"10 000","country":"Croatia","geoPoint":{"lat":45.81444,"lon":15.97798}},{"facility":"Novo Nordisk Investigational Site","city":"Zagreb","zip":"10000","country":"Croatia","geoPoint":{"lat":45.81444,"lon":15.97798}},{"facility":"Novo Nordisk Investigational Site","city":"Athens","zip":"115 25","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Novo Nordisk Investigational Site","city":"Athens","zip":"GR-10552","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Novo Nordisk Investigational Site","city":"Thessaloniki","zip":"GR-54636","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Novo Nordisk Investigational Site","city":"Thessaloniki","zip":"GR-54642","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Novo Nordisk Investigational Site","city":"Thessaloniki","zip":"GR-54643","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Novo Nordisk Investigational Site","city":"Thessaloniki","zip":"GR-57001","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Novo Nordisk Investigational Site","city":"Thessaloniki","zip":"GR-57010","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Novo Nordisk Investigational Site","city":"Budapest","zip":"1139","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Novo Nordisk Investigational Site","city":"Budapest","zip":"1152","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Novo Nordisk Investigational Site","city":"Cegléd","zip":"2700","country":"Hungary","geoPoint":{"lat":47.17266,"lon":19.79952}},{"facility":"Novo Nordisk Investigational Site","city":"Nyíregyhaza","zip":"4400","country":"Hungary"},{"facility":"Novo Nordisk Investigational Site","city":"Salgótarján","zip":"3100","country":"Hungary","geoPoint":{"lat":48.09872,"lon":19.80303}},{"facility":"Novo Nordisk Investigational Site","city":"Szekszárd","zip":"7100","country":"Hungary","geoPoint":{"lat":46.34723,"lon":18.71189}},{"facility":"Novo Nordisk Investigational Site","city":"Bologna","zip":"40138","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Novo Nordisk Investigational Site","city":"Lucca","zip":"55100","country":"Italy","geoPoint":{"lat":43.84369,"lon":10.50447}},{"facility":"Novo Nordisk Investigational Site","city":"Palermo","zip":"90127","country":"Italy","geoPoint":{"lat":38.1166,"lon":13.3636}},{"facility":"Novo Nordisk Investigational Site","city":"Roma","zip":"00133","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Novo Nordisk Investigational Site","city":"Roma","zip":"00161","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Novo Nordisk Investigational Site","city":"Siena","zip":"53100","country":"Italy","geoPoint":{"lat":43.31822,"lon":11.33064}},{"facility":"Novo Nordisk Investigational Site","city":"Bialystok","zip":"15-435","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"Novo Nordisk Investigational Site","city":"Lublin","zip":"20-538","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Novo Nordisk Investigational Site","city":"Puławy","zip":"24-100","country":"Poland","geoPoint":{"lat":51.41655,"lon":21.96939}},{"facility":"Novo Nordisk Investigational Site","city":"Warsaw","zip":"00-911","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Novo Nordisk Investigational Site","city":"Wroclaw","zip":"50-127","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Novo Nordisk Investigational Site","city":"Zabrze","zip":"41-800","country":"Poland","geoPoint":{"lat":50.32492,"lon":18.78576}},{"facility":"Novo Nordisk Investigational Site","city":"Kazan'","zip":"420012","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"Novo Nordisk Investigational Site","city":"Moscow","zip":"117292","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Novo Nordisk Investigational Site","city":"Saint Petersburg","zip":"194291","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Novo Nordisk Investigational Site","city":"Saint Petersburg","zip":"194356","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Novo Nordisk Investigational Site","city":"Saratov","zip":"410053","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"Novo Nordisk Investigational Site","city":"Tyumen","zip":"625023","country":"Russia","geoPoint":{"lat":57.15222,"lon":65.52722}},{"facility":"Novo Nordisk Investigational Site","city":"Kragujevac","zip":"34000","country":"Serbia","geoPoint":{"lat":44.01667,"lon":20.91667}},{"facility":"Novo Nordisk Investigational Site","city":"Niš","zip":"18000","country":"Serbia","geoPoint":{"lat":43.32472,"lon":21.90333}},{"facility":"Novo Nordisk Investigational Site","city":"Novi Sad","zip":"21000","country":"Serbia","geoPoint":{"lat":45.25167,"lon":19.83694}},{"facility":"Novo Nordisk Investigational Site","city":"Almería","zip":"04001","country":"Spain","geoPoint":{"lat":36.83814,"lon":-2.45974}},{"facility":"Novo Nordisk Investigational Site","city":"Centelles (Barcelona)","zip":"08540","country":"Spain","geoPoint":{"lat":41.79746,"lon":2.21902}},{"facility":"Novo Nordisk Investigational Site","city":"L'Hospitalet de Llobregat","zip":"08907","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Novo Nordisk Investigational Site","city":"La Roca Del Vallés","zip":"08430","country":"Spain"},{"facility":"Novo Nordisk Investigational Site","city":"Pozuelo de Alarcón","zip":"28223","country":"Spain","geoPoint":{"lat":40.43293,"lon":-3.81338}},{"facility":"Novo Nordisk Investigational Site","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Novo Nordisk Investigational Site","city":"Seville","zip":"41010","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Novo Nordisk Investigational Site","city":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Novo Nordisk Investigational Site","city":"Vic (Barcelona)","zip":"08500","country":"Spain","geoPoint":{"lat":41.93012,"lon":2.25486}},{"facility":"Novo Nordisk Investigational Site","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Novo Nordisk Investigational Site","city":"Bangkoknoi, Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}}]},"referencesModule":{"references":[{"pmid":"31530666","type":"RESULT","citation":"Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SO, Lingvay I, Sondergaard AL, Treppendahl MB, Montanya E; PIONEER 2 Investigators. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019 Dec;42(12):2272-2281. doi: 10.2337/dc19-0883. Epub 2019 Sep 17."},{"pmid":"35064550","type":"RESULT","citation":"Eliasson B, Ericsson A, Fridhammar A, Nilsson A, Persson S, Chubb B. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting. Pharmacoecon Open. 2022 May;6(3):343-354. doi: 10.1007/s41669-021-00317-z. Epub 2022 Jan 21."},{"pmid":"35373893","type":"RESULT","citation":"Aroda VR, Bauer R, Christiansen E, Haluzik M, Kallenbach K, Montanya E, Rosenstock J, Meier JJ. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes Obes Metab. 2022 Jul;24(7):1338-1350. doi: 10.1111/dom.14710. Epub 2022 May 9."},{"pmid":"37178435","type":"DERIVED","citation":"Pulleyblank R, Larsen NB. Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study. Pharmacoecon Open. 2023 Jul;7(4):579-591. doi: 10.1007/s41669-023-00416-z. Epub 2023 May 13."},{"pmid":"36056351","type":"DERIVED","citation":"Mosenzon O, Capehorn MS, De Remigis A, Rasmussen S, Weimers P, Rosenstock J. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovasc Diabetol. 2022 Sep 2;21(1):172. doi: 10.1186/s12933-022-01585-7."},{"pmid":"32827435","type":"DERIVED","citation":"Lingvay I, Capehorn MS, Catarig AM, Johansen P, Lawson J, Sandberg A, Shaw R, Paine A. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. J Clin Endocrinol Metab. 2020 Dec 1;105(12):e4593-604. doi: 10.1210/clinem/dgaa577."},{"pmid":"32267058","type":"DERIVED","citation":"Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes Obes Metab. 2020 Aug;22(8):1263-1277. doi: 10.1111/dom.14054. Epub 2020 May 13."},{"pmid":"31903692","type":"DERIVED","citation":"Husain M, Bain SC, Jeppesen OK, Lingvay I, Sorrig R, Treppendahl MB, Vilsboll T. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020 Mar;22(3):442-451. doi: 10.1111/dom.13955. Epub 2020 Feb 5."}],"seeAlsoLinks":[{"label":"Clinical Trials at Novo Nordisk","url":"http://novonordisk-trials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Data presented in \"participant flow\" is based on the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.","recruitmentDetails":"The trial was conducted at 108 sites in 12 countries as follows: Argentina (4), Brazil (3), Croatia (4), Greece (7), Hungary (7), Italy (5), Poland (6), Russian Federation (6), Serbia (5), Spain (8), Thailand (3), United States (46). 1 site each in Croatia and Italy, and 2 sites in the United States screened, but didn't randomise any subjects.","groups":[{"id":"FG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"FG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","comment":"One participant was duplicate, hence removed from 'started' population.","achievements":[{"groupId":"FG000","numSubjects":"411"},{"groupId":"FG001","numSubjects":"410"}]},{"type":"Full Analysis Set (FAS)","achievements":[{"groupId":"FG000","numSubjects":"411"},{"groupId":"FG001","numSubjects":"410"}]},{"type":"Safety Analysis Set (SAS)","achievements":[{"groupId":"FG000","numSubjects":"410"},{"groupId":"FG001","numSubjects":"409"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"400"},{"groupId":"FG001","numSubjects":"387"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"23"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Died","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"FAS comprised of all randomised participants; however, one subject was randomised twice and thereby only included in FAS once.","groups":[{"id":"BG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"BG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"411"},{"groupId":"BG001","value":"410"},{"groupId":"BG002","value":"821"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57","spread":"10"},{"groupId":"BG001","value":"58","spread":"10"},{"groupId":"BG002","value":"58","spread":"10"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"205"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"406"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"206"},{"groupId":"BG001","value":"209"},{"groupId":"BG002","value":"415"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"199"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"320"},{"groupId":"BG001","value":"302"},{"groupId":"BG002","value":"622"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","description":"Race","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Race","categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"355"},{"groupId":"BG001","value":"353"},{"groupId":"BG002","value":"708"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"59"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"49"}]},{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"HbA1c","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"percentage of HbA1c","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.1","spread":"0.9"},{"groupId":"BG001","value":"8.1","spread":"0.9"},{"groupId":"BG002","value":"8.1","spread":"0.9"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c","description":"Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 26. The endpoint was evaluated based on data from the in-trial observation period which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage-point of HbA1c","timeFrame":"Week 0, week 26","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"In-trial","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.1"},{"groupId":"OG001","value":"-0.9","spread":"0.9"}]}]},{"title":"On-treatment without rescue medication","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"347"},{"groupId":"OG001","value":"378"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"1.1"},{"groupId":"OG001","value":"-0.9","spread":"0.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an analysis of covariance (ANCOVA) model with treatment and region as categorical fixed effects and baseline HbA1c value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"This hypothesis was controlled for multiplicity. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand). A value of 0.4% (the non-inferiority margin) was added to imputed values at week 26 for the oral semaglutide treatment arm only.","pValue":"< 0.0001","pValueComment":"Unadjusted two-sided p-value for test of no difference from the non-inferiority margin (non-inferiority). The non-inferiority margin was 0.4%.","statisticalMethod":"Pattern mixture model","paramType":"Treatment difference","paramValue":"-0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.6","ciUpperLimit":"-0.3","estimateComment":"Oral semaglutide 14 mg - Empagliflozin 25 mg"},{"groupIds":["OG000","OG001"],"groupDescription":"The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an ANCOVA model with treatment and region as categorical fixed effects and baseline HbA1c value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"This hypothesis was controlled for multiplicity. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand).","pValue":"< 0.0001","pValueComment":"Unadjusted two-sided p-value for test of no difference from 0 (superiority).","statisticalMethod":"Pattern mixture model","paramType":"Treatment difference","paramValue":"-0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.6","ciUpperLimit":"-0.3","estimateComment":"Oral semaglutide 14 mg - Empagliflozin 25 mg"},{"groupIds":["OG000","OG001"],"groupDescription":"The analysis was based on a mixed model for repeated measurements (MMRM) that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment and region as categorical fixed effects and the baseline HbA1c value as a covariate, all nested within visit, and an unstructured residual covariance matrix.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).","pValue":"<0.0001","pValueComment":"Unadjusted two-sided p-value for test of no difference from the non-inferiority margin (non-inferiority). The non-inferiority margin was 0.4%.","statisticalMethod":"MMRM","paramType":"Treatment difference","paramValue":"-0.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.7","ciUpperLimit":"-0.4","estimateComment":"Oral semaglutide 14 mg - Empagliflozin 25 mg"},{"groupIds":["OG000","OG001"],"groupDescription":"The analysis was based on a MMRM that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment and region as categorical fixed effects and the baseline HbA1c value as a covariate, all nested within visit, and an unstructured residual covariance matrix.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).","pValue":"<0.0001","pValueComment":"Unadjusted two-sided p-value for test of no difference from 0 (superiority).","statisticalMethod":"MMRM","paramType":"Treatment difference","paramValue":"-0.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.7","ciUpperLimit":"-0.4","estimateComment":"Oral semaglutide 14 mg - Empagliflozin 25 mg"}]},{"type":"SECONDARY","title":"Change in Body Weight (Kg)","description":"Change from baseline (week 0) in body weight was evaluated at week 26. The endpoint was evaluated based on data from the in-trial observation period which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Kilogram (Kg)","timeFrame":"Week 0, week 26","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"In-trial","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"393"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"4.4"},{"groupId":"OG001","value":"-3.8","spread":"3.8"}]}]},{"title":"On-treatment without rescue medication","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"378"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"4.4"},{"groupId":"OG001","value":"-3.9","spread":"3.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an ANCOVA model with treatment and region as categorical fixed effects and baseline body weight value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"This hypothesis was controlled for multiplicity. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand).","pValue":"= 0.7593","pValueComment":"Unadjusted two-sided p-value for test of no difference from 0 (superiority).","statisticalMethod":"Pattern mixture model","paramType":"Treatment difference","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.7","ciUpperLimit":"0.5","estimateComment":"Oral semaglutide 14 mg - Empagliflozin 25 mg"},{"groupIds":["OG000","OG001"],"groupDescription":"The analysis was based on a MMRM that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment and region as categorical fixed effects and the baseline body weight value as a covariate, all nested within visit, and an unstructured residual covariance matrix.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).","pValue":"= 0.1358","pValueComment":"Unadjusted two-sided p-value for test of no difference from 0 (superiority).","statisticalMethod":"MMRM","paramType":"Treatment difference","paramValue":"-0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.0","ciUpperLimit":"0.1","estimateComment":"Oral semaglutide 14 mg - Empagliflozin 25 mg"}]},{"type":"SECONDARY","title":"Change in HbA1c (%)","description":"Change from baseline (week 0) in HbA1c was evaluated at week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of HbA1c","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"382"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.2","lowerLimit":"1.2"},{"groupId":"OG001","value":"-0.9","spread":"1.0","lowerLimit":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (kg)","description":"Change from baseline (week 0) in body weight was evaluated at week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Kg","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"5.5","lowerLimit":"5.5"},{"groupId":"OG001","value":"-3.7","spread":"4.3","lowerLimit":"4.3"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose","description":"Change from baseline (week 0) in fasting plasma glucose was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimoles per liter (mmol/L)","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"388"},{"groupId":"OG001","value":"391"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.01","spread":"2.56"},{"groupId":"OG001","value":"-2.08","spread":"2.17"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"380"},{"groupId":"OG001","value":"378"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.04","spread":"2.50"},{"groupId":"OG001","value":"-2.14","spread":"2.36"}]}]}]},{"type":"SECONDARY","title":"Change in SMPG : Mean of the 7-point Profile","description":"Change from baseline (week 0) in mean of the 7-point self-measured plasma glucose (SMPG) (i.e. before and after breakfast, lunch and dinner, and at bedtime) profile was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"351"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"2.1"},{"groupId":"OG001","value":"-1.9","spread":"2.1"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"349"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"2.3"},{"groupId":"OG001","value":"-2.1","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Change in SMPG : Mean Postprandial Increment Over All Meals","description":"Change from baseline (week 0) in mean postprandial glucose increment was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"351"},{"groupId":"OG001","value":"354"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.8"},{"groupId":"OG001","value":"-0.4","spread":"2.0"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"350"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.8"},{"groupId":"OG001","value":"-0.4","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting C-peptide (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting C-peptide (Nanomoles per liter \\[nmol/L\\]) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of C-peptide","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"381"},{"groupId":"OG001","value":"387"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"35.7"},{"groupId":"OG001","value":"0.89","spread":"29.4"}]}]},{"title":"week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"381"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"37.2"},{"groupId":"OG001","value":"0.92","spread":"31.6"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Insulin (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting insulin (picomoles per liter \\[pmol/L\\]) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of insulin","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"386"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"50.5"},{"groupId":"OG001","value":"0.77","spread":"54.1"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"378"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":"52.8"},{"groupId":"OG001","value":"0.77","spread":"53.7"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Pro-insulin (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting pro-insulin (pmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of pro-insulin","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"388"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"74.6"},{"groupId":"OG001","value":"0.66","spread":"61.9"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"377"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":"80.5"},{"groupId":"OG001","value":"0.69","spread":"57.8"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Glucagon (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting glucagon (picograms per milliliter \\[pg/mL\\]) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of glucagon","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"28.0"},{"groupId":"OG001","value":"1.01","spread":"27.5"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"27.8"},{"groupId":"OG001","value":"0.95","spread":"27.6"}]}]}]},{"type":"SECONDARY","title":"Change in HOMA-IR (Ratio to Baseline)","description":"Change from baseline (week 0) in homeostatic model assessment index of insulin resistance (HOMA-IR) (%) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of HOMA-IR","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"63.8"},{"groupId":"OG001","value":"0.61","spread":"58.7"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"374"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"64.9"},{"groupId":"OG001","value":"0.60","spread":"60.4"}]}]}]},{"type":"SECONDARY","title":"Change in HOMA-B (Ratio to Baseline)","description":"Change from baseline (week 0) in homeostatic model assessment index of beta-cell function (HOMA-B) (%) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of HOMA-B","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":"69.5"},{"groupId":"OG001","value":"1.16","spread":"65.0"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"374"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":"72.9"},{"groupId":"OG001","value":"1.17","spread":"69.9"}]}]}]},{"type":"SECONDARY","title":"Change in C-reactive Protein (Ratio to Baseline)","description":"Change from baseline (week 0) in C-reactive protein (milligrams per liter \\[mg/L\\]) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of C-reactive protein","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"388"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"121.5"},{"groupId":"OG001","value":"0.98","spread":"115.7"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"381"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"129.7"},{"groupId":"OG001","value":"0.90","spread":"126.3"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (%)","description":"Relative change from baseline (week 0) in body weight (kg) was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage change","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"393"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.34","spread":"4.51"},{"groupId":"OG001","value":"-4.14","spread":"4.12"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.38","spread":"5.76"},{"groupId":"OG001","value":"-4.09","spread":"4.78"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index","description":"Change from baseline (week 0) in body mass index (BMI) was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Kilograms per square meter (kg/m^2)","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"1.6"},{"groupId":"OG001","value":"-1.4","spread":"1.4"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"2.0"},{"groupId":"OG001","value":"-1.4","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Change from baseline (week 0) in waist circumference was evaluated at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Centimetre (cm)","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"393"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"5.1"},{"groupId":"OG001","value":"-2.9","spread":"5.0"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"378"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"5.5"},{"groupId":"OG001","value":"-2.9","spread":"5.8"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Total Cholesterol (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting total cholesterol (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of total cholesterol","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"18.1"},{"groupId":"OG001","value":"1.02","spread":"15.2"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"381"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"18.1"},{"groupId":"OG001","value":"1.01","spread":"17.1"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting LDL Cholesterol (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting low density lipoprotein (LDL) cholesterol (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of LDL cholesterol","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"38.3"},{"groupId":"OG001","value":"1.03","spread":"24.6"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"381"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"30.1"},{"groupId":"OG001","value":"1.03","spread":"27.2"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting HDL Cholesterol (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting high density lipoprotein (HDL) cholesterol (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of HDL cholesterol","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"13.0"},{"groupId":"OG001","value":"1.07","spread":"15.9"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"381"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"13.9"},{"groupId":"OG001","value":"1.06","spread":"14.0"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting VLDL Cholesterol (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting very low density lipoprotein (VLDL) cholesterol (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of VLDL cholesterol","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"39.0"},{"groupId":"OG001","value":"0.91","spread":"34.7"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"381"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"39.3"},{"groupId":"OG001","value":"0.90","spread":"37.6"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Free Fatty Acids (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting free fatty acids (FFA) (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. Because of an issue with the handling of the blood samples for FFA, all FFA data are considered invalid for this trial; thus, no conclusion with regards to FFA levels can be made based on the FFA data. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of FFA","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"390"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"51.3"},{"groupId":"OG001","value":"1.05","spread":"46.9"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"380"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"53.0"},{"groupId":"OG001","value":"0.97","spread":"49.2"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Triglycerides (Ratio to Baseline)","description":"Change from baseline (week 0) in fasting triglycerides (mmol/L) at week 26 and week 52 is presented as ratio to baseline. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of triglycerides","timeFrame":"Week 0, week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"40.5"},{"groupId":"OG001","value":"0.90","spread":"36.1"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"381"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"42.3"},{"groupId":"OG001","value":"0.90","spread":"39.3"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve HbA1c <7.0 % (53 mmol/Mol) ADA Target (Yes/no)","description":"Participants who achieved HbA1c \\<7.0% (53 mmol/mol) (American Diabetes Association (ADA) target) at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"158"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"237"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"382"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"165"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"217"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve HbA1c ≤6.5% (48 mmol/Mol), AACE Target (Yes/no)","description":"Participants who achieved HbA1c ≤6.5% (48 mmol/mol) (American Association of Clinical Endocrinologists (AACE) target) at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"68"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"327"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"382"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"83"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"299"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve Weight Loss ≥5% (Yes/no)","description":"Participants who achieved weight loss of ≥5% at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"393"},{"groupId":"OG001","value":"396"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"143"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"253"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"150"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"233"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve Weight Loss ≥10% (Yes/no)","description":"Participants who achieved weight loss of ≥10% at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"393"},{"groupId":"OG001","value":"396"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"27"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"344"},{"groupId":"OG001","value":"369"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"30"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"353"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve HbA1c <7.0 % (53 mmol/Mol) Without Hypoglycaemia (Severe or BG Confirmed Symptomatic Hypoglycaemia) and no Weight Gain (Yes/no)","description":"Participants who achieved HbA1c \\<7.0% (53 mmol/mol) without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia and without weight gain at week 26 and week 52. Severe or BG-confirmed symptomatic hypoglycaemia: an episode, that is severe according to the ADA classification or BG-confirmed by a plasma glucose value \\<3.1 mmol/L with symptoms consistent with hypoglycaemia. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"141"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"254"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"382"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"149"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"233"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve HbA1c Reduction ≥1% (10.9 mmol/Mol) and Weight Loss ≥3% (Yes/no)","description":"Participants who achieved HbA1c reduction ≥1%-point and weight loss of ≥3% at week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 26 and week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"111"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"284"}]}]},{"title":"week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"382"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"101"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"281"}]}]}]},{"type":"SECONDARY","title":"Time to Additional Anti-diabetic Medication","description":"Presented results are the number of participants who had taken additional anti-diabetic medication anytime during the periods, from week 0 to week 26 and week 0 to week 52. Additional anti-diabetic medication: use of new anti-diabetic medication for more than 21 days with the initiation at or after randomisation (week 0) and before (planned) end-of-treatment (week 26/week 52), and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline) for more than 21 days with the intensification at or after randomisation and before (planned) end-of-treatment. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Weeks 0-52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 0-26","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"13"}]}]},{"title":"Week 0-52","categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"56"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Time to initiation of additional anti-diabetic medication was analysed using a Cox proportional hazards model with treatment and region as categorical fixed effects and baseline HbA1c as covariate. Withdrawal for any reason or lost to follow-up contributed to the analysis as events (initiation of additional anti-diabetic medication). Censoring time was one day before planned end of treatment.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"This hypothesis was not controlled for multiplicity.","pValue":"0.3552","pValueComment":"Unadjusted two-sided p-value for test of no difference from 1.","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"0.85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.60","ciUpperLimit":"1.20","estimateComment":"Oral semaglutide 14 mg / Empagliflozin 25 mg"}]},{"type":"SECONDARY","title":"Time to Rescue Medication","description":"Presented results are the number of participants who had taken rescue medication anytime during the periods, from week 0 to week 26 and week 0 to week 52. Rescue medication: use of new antidiabetic medication as add-on to trial product and used for more than 21 days with the initiation at or after randomisation (week 0) and before last day on trial product, and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline for more than 21 days with the intensification at or after randomisation and before last day on trial product. Results are based on the data from the on-treatment without rescue medication observation period. On-treatment without rescue medication observation period: the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Weeks 0-52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 0-26","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}]},{"title":"Week 0-52","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"44"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Time to initiation of rescue medication was analysed using a Cox proportional hazards model with treatment and region as categorical fixed effects and baseline HbA1c as covariate. Censoring time was one day before last day on trial product.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"This hypothesis was not controlled for multiplicity.","pValue":"0.2250","pValueComment":"Unadjusted two-sided p-value for test of no difference from 1.","statisticalMethod":"Cox proportional hazards model","paramType":"Hazard Ratio (HR)","paramValue":"0.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.47","ciUpperLimit":"1.19","estimateComment":"Oral semaglutide 14 mg / Empagliflozin 25 mg"}]},{"type":"SECONDARY","title":"Number of Treatment-emergent Adverse Events (TEAE)","description":"A treatment-emergent adverse event (TEAE) is defined as an adverse event (AE) with onset in the on-treatment observation period (the time period where participants are considered treated with trial product) and was assessed up to approximately 57 weeks (52-week treatment period plus the 5-week follow-up period).","populationDescription":"Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"Weeks 0-57","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1022"},{"groupId":"OG001","value":"948"}]}]}]},{"type":"SECONDARY","title":"Change in Amylase (Ratio to Baseline)","description":"Change from baseline (week 0) in amylase (units per liter \\[U/L\\]) at week 26 and week 52 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of amylase","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"382"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"30.1"},{"groupId":"OG001","value":"1.10","spread":"24.8"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"359"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"31.5"},{"groupId":"OG001","value":"1.11","spread":"26.8"}]}]}]},{"type":"SECONDARY","title":"Change in Lipase (Ratio to Baseline)","description":"Change from baseline (week 0) in lipase (U/L) at week 26 and week 52 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of lipase","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"382"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":"62.0"},{"groupId":"OG001","value":"1.10","spread":"50.8"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"359"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","spread":"63.6"},{"groupId":"OG001","value":"1.07","spread":"47.2"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse Rate","description":"Change from baseline (week 0) in pulse rate was evaluated at week 26 and week 52. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Beats/minute","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"classes":[{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"10"},{"groupId":"OG001","value":"-2","spread":"9"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"336"},{"groupId":"OG001","value":"364"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"10"},{"groupId":"OG001","value":"-2","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in Blood Pressure (Systolic and Diastolic Blood Pressure)","description":"Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated at week 26 and week 52. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimeters of mercury (mmHg)","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"classes":[{"title":"SBP, week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"15"},{"groupId":"OG001","value":"-5","spread":"14"}]}]},{"title":"SBP, week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"364"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"13"},{"groupId":"OG001","value":"-4","spread":"15"}]}]},{"title":"DBP, week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"9"},{"groupId":"OG001","value":"-3","spread":"9"}]}]},{"title":"DBP, week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"364"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"10"},{"groupId":"OG001","value":"-3","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in ECG","description":"Change from baseline (week 0) in electrocardiogram (ECG) was evaluated at week 26 and week 52. Change from baseline results are presented as shift in findings (normal, abnormal and not clinically significant (NCS), and abnormal and clinically significant (CS)) from week 0 to week 26 and week 52. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"classes":[{"title":"Normal (week 0) to normal (week 26)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"242"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"203"}]}]},{"title":"Normal (week 0) to abnormal NCS (week 26)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"242"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"37"}]}]},{"title":"Normal (week 0) to abnormal CS (week 26)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"242"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Abnormal NCS (week 0) to normal (week 26)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"41"}]}]},{"title":"Abnormal NCS (week 0) to abnormal NCS (week 26)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"110"}]}]},{"title":"Abnormal NCS (week 0) to abnormal CS (week 26)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Abnormal CS (week 0) to normal (week 26)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Abnormal CS (week 0) CS to abnormal NCS (week 26)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Abnormal CS (week 0) to abnormal CS (week 26)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Normal (week 0) to normal (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"235"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"194"}]}]},{"title":"Normal (week 0) to abnormal NCS (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"235"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"39"}]}]},{"title":"Normal (week 0) to abnormal CS (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"235"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Abnormal (week 0) NCS to normal (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"144"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"45"}]}]},{"title":"Abnormal (week 0) NCS to abnormal NCS (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"144"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"97"}]}]},{"title":"Abnormal (week 0) NCS to abnormal CS (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"144"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Abnormal CS (week 0) to normal (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Abnormal CS (week 0) to abnormal NCS (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Abnormal CS (week 0) to abnormal CS (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Change in Physical Examination","description":"The physical examination findings (normal, abnormal NCS and abnormal CS) of the participants at week -2 and week 52 are presented for the following examinations: Cardiovascular system, Nervous system (central and peripheral); Gastrointestinal system, incl. mouth; General appearance; Head (ears, eyes, nose), throat, neck; Lymph node palpation; Musculoskeletal system; Respiratory system; Skin; Thyroid gland. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week -2, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"classes":[{"title":"Cardiovascular system (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"381"},{"groupId":"OG001","value":"372"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"34"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]},{"title":"Cardiovascular system (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"382"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"351"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"29"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"Nervous system (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"390"},{"groupId":"OG001","value":"376"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"30"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"Nervous system (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"371"},{"groupId":"OG001","value":"365"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Gastrointestinal system (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"384"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Gastrointestinal system (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"382"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"360"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"22"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"General appearance (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"354"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"49"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"}]}]},{"title":"General appearance (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"345"},{"groupId":"OG001","value":"338"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"41"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]},{"title":"Head, throat, neck (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"382"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"26"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Head, throat, neck (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"362"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"19"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Lymph node palpation (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"409"},{"groupId":"OG001","value":"409"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Lymph node palpation (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"381"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"381"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Musculoskeletal system (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"384"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"25"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Musculoskeletal system (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"370"},{"groupId":"OG001","value":"363"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"20"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Respiratory system (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"400"},{"groupId":"OG001","value":"403"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Respiratory system (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"382"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"378"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Skin (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"354"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"53"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Skin (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"346"},{"groupId":"OG001","value":"340"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"42"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Thyroid gland (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"399"},{"groupId":"OG001","value":"389"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Thyroid gland (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"367"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"16"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change in Eye Examination","description":"The eye examination findings (normal, abnormal NCS and abnormal CS) of the participants at baseline (week -2) and week 52 are presented. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week -2, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"classes":[{"title":"Left eye (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"409"},{"groupId":"OG001","value":"407"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"295"},{"groupId":"OG001","value":"295"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"102"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}]}]},{"title":"Left eye (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"372"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"269"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"93"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"}]}]},{"title":"Right eye (week -2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"409"},{"groupId":"OG001","value":"409"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"294"},{"groupId":"OG001","value":"293"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"107"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"}]}]},{"title":"Right eye (week 52)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"373"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"267"},{"groupId":"OG001","value":"269"}]},{"title":"Abnormal NCS","measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"93"}]},{"title":"Abnormal CS","measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Anti-semaglutide Binding Antibodies (Yes/no)","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. Number of participants who measured with anti-semaglutide binding antibodies anytime during post-baseline visits (week 0 to week 57) are presented. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Weeks 0-57","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"403"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Anti-semaglutide Neutralising Antibodies (Yes/no)","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. Number of participants who measured with anti-semaglutide neutralising antibodies anytime during post-baseline visits (week 0 to week 57) are presented. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Weeks 0-57","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"403"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Anti-semaglutide Binding Antibodies Cross Reacting With Native GLP-1 (Yes/no)","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. Number of participants who measured with anti-semaglutide binding antibodies cross reacting with native glucagon-like peptide-1 (GLP-1) anytime during post-baseline visits (week 0 to week 57) are presented. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Weeks 0-57","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"403"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Anti-semaglutide Neutralising Antibodies Cross Reacting With Native GLP-1 (Yes/no)","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. Number of participants who measured with anti-semaglutide neutralising antibodies cross reacting with native GLP-1 anytime during post-baseline visits (week 0 to week 57) are presented. The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Weeks 0-57","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"403"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Anti-semaglutide Binding Antibody Levels","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. It is based on the data from participants who were measured with anti-semaglutide antibodies anytime during post-baseline visits (week 0 to week 57). Results are presented as percentage of bound radioactivity-labelled semaglutide /total added radioactivity-labelled semaglutide (%B/T). The results are based on the data from the in-trial observation period. In trial observation period: the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication or premature discontinuation of trial product.","populationDescription":"Overall number of participants analysed = participants who were found positive for anti-semaglutide antibodies.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"%B/T","timeFrame":"Weeks 0-57","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"classes":[{"title":"Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.75","spread":"0.00"}]}]},{"title":"Week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":"0.00"}]}]},{"title":"Week 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 38","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"title":"Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent Severe or Blood Glucose-confirmed Symptomatic Hypoglycaemic Episodes","description":"Treatment-emergent hypoglycaemia is an episode with onset in the on-treatment observation period (the time period where participants are considered treated with trial product) and was assessed up to approximately 57 weeks (52-week treatment period plus the 5-week follow-up period). Severe or BG-confirmed symptomatic hypoglycaemia is an episode that is severe according to the American Diabetes Association classification or blood glucose-confirmed by a plasma glucose value \\<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes","timeFrame":"Weeks 0-57","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}]}]},{"type":"SECONDARY","title":"Participants With Treatment-emergent Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes (Yes/no)","description":"Number of participants with treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes was recorded during week 0-57. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Weeks 0-57","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}]}]},{"type":"SECONDARY","title":"Semaglutide Plasma Concentrations for Population PK Analyses","description":"Semaglutide plasma concentrations were measured after 25 minutes post-dose at week 4, 26 and 52. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Nanomoles per liter (nmol/L)","timeFrame":"Weeks 0-52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"}]}],"classes":[{"title":"Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"84.5"}]}]},{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"348"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":"112.4"}]}]},{"title":"Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"331"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":"136.6"}]}]}]},{"type":"SECONDARY","title":"SNAC Plasma Concentrations","description":"This outcome measure is only applicable for the oral semaglutide 14 mg treatment arm. Sodium N-\\[8-(2-hydroxybenzoyl) amino\\]caprylate (SNAC) plasma concentrations were measured after 25 and 40 minutes post-dose at week 4, 26 and 52. Results are based on the data from the on-treatment observation period. On-treatment observation period: the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Nanograms per milliliter (ng/mL)","timeFrame":"Weeks 0-52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"}]}],"classes":[{"title":"Week 4: 25 minutes post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"390"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"559","spread":"224.6"}]}]},{"title":"Week 4: 40 minutes post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"375","spread":"210.4"}]}]},{"title":"Week 26: 25 minutes post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"350"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"474","spread":"272.7"}]}]},{"title":"Week 26: 40 minutes post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"349"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"373","spread":"200.6"}]}]},{"title":"Week 52: 25 minutes post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"331"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"448","spread":"377.5"}]}]},{"title":"Week 52: 40 minutes post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"331"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"301","spread":"290.2"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form Health Survey Version 2.0 (SF-36v2™, Acute Version) Health Survey: Scores From the 8 Domains and Summaries of the Physical Component Score (PCS) and the Mental Component Score (MCS)","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The 0-100 scale scores (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively of the 2009 U.S. general population. Change from baseline (week 0) in the domain scores and component summary (PCS and MCS) scores were evaluated at weeks 26 and 52. A positive change score indicates an improvement since baseline. Results are based on the data from the in-trial observation period.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26: Physical Functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":"7.35"},{"groupId":"OG001","value":"0.99","spread":"7.11"}]}]},{"title":"Week 52: Physical Functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"6.79"},{"groupId":"OG001","value":"0.84","spread":"7.32"}]}]},{"title":"Week 26: Role functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"6.82"},{"groupId":"OG001","value":"0.56","spread":"8.36"}]}]},{"title":"Week 52: Role functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"382"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"6.78"},{"groupId":"OG001","value":"0.52","spread":"7.93"}]}]},{"title":"Week 26: Bodily pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"9.77"},{"groupId":"OG001","value":"1.04","spread":"9.53"}]}]},{"title":"Week 52: Bodily pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"10.07"},{"groupId":"OG001","value":"1.20","spread":"9.54"}]}]},{"title":"Week 26: General health","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.26","spread":"6.59"},{"groupId":"OG001","value":"1.36","spread":"6.56"}]}]},{"title":"Week 52: General health","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"7.35"},{"groupId":"OG001","value":"1.86","spread":"7.66"}]}]},{"title":"Week 26: Vitality","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"7.58"},{"groupId":"OG001","value":"0.49","spread":"7.60"}]}]},{"title":"Week 52: Vitality","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"7.72"},{"groupId":"OG001","value":"1.15","spread":"7.48"}]}]},{"title":"Week 26: Social functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"7.28"},{"groupId":"OG001","value":"-0.54","spread":"8.15"}]}]},{"title":"Week 52: Social functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"8.35"},{"groupId":"OG001","value":"-0.54","spread":"8.63"}]}]},{"title":"Week 26: Role emotional","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"9.47"},{"groupId":"OG001","value":"0.53","spread":"9.49"}]}]},{"title":"Week 52: Role emotional","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"382"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"9.63"},{"groupId":"OG001","value":"0.42","spread":"9.93"}]}]},{"title":"Week 26: Mental health","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"8.06"},{"groupId":"OG001","value":"-0.03","spread":"8.70"}]}]},{"title":"Week 52: Mental health","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"8.71"},{"groupId":"OG001","value":"-0.03","spread":"9.21"}]}]},{"title":"Week 26: PCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"6.36"},{"groupId":"OG001","value":"1.21","spread":"6.39"}]}]},{"title":"Week 52: PCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"382"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"6.26"},{"groupId":"OG001","value":"1.36","spread":"6.50"}]}]},{"title":"Week 26: MCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"7.54"},{"groupId":"OG001","value":"-0.23","spread":"8.40"}]}]},{"title":"Week 52: MCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"382"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"8.36"},{"groupId":"OG001","value":"-0.09","spread":"8.64"}]}]}]},{"type":"SECONDARY","title":"Change in CoEQ: Scores From the 4 Domains and the 19 Items","description":"Change from baseline (week 0) in Control of Eating Questionnaire (CoEQ) was evaluated at weeks 26 and 52. The CoEQ comprised 19 items to assess the intensity and type of food cravings, as well as subjective sensation of appetite and mood, with the 4 domains: 'craving control' (items 9-12, 19), 'positive mood' (items 5-8), 'craving for savoury' (items 4, 16-18) and 'craving for sweet' (items 3, 13-15). The 19 items were scored on an 11-point graded response scale ranging from 10 to 0, with items relating to each of the 4 domains being averaged to create a final score. A low score in the domains 'craving for sweet and 'craving for savoury' represents a low level of craving; whereas a high score in the domains 'craving control' and 'positive mood' represents good control and a good mood, respectively. Results are based on the data from the in-trial observation period.","populationDescription":"Overall number of participants analyzed = FAS which comprised all randomised participants, however, one participant was randomised twice and thereby included only once in the FAS. Number Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 26, week 52","groups":[{"id":"OG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52)."},{"id":"OG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"410"}]}],"classes":[{"title":"Week 26: Craving control","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"2.60"},{"groupId":"OG001","value":"0.21","spread":"2.26"}]}]},{"title":"Week 52: Craving control","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"2.54"},{"groupId":"OG001","value":"0.18","spread":"2.38"}]}]},{"title":"Week 26: Positive Mood","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"1.52"},{"groupId":"OG001","value":"0.19","spread":"1.62"}]}]},{"title":"Week 52: Positive Mood","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"1.75"},{"groupId":"OG001","value":"0.17","spread":"1.64"}]}]},{"title":"Week 26: Craving for Savoury","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"2.13"},{"groupId":"OG001","value":"-0.54","spread":"2.05"}]}]},{"title":"Week 52: Craving for Savoury","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"2.16"},{"groupId":"OG001","value":"-0.44","spread":"2.14"}]}]},{"title":"Week 26: Craving for Sweet","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"2.15"},{"groupId":"OG001","value":"-0.21","spread":"2.04"}]}]},{"title":"Week 52: Craving for Sweet","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"2.23"},{"groupId":"OG001","value":"-0.17","spread":"2.13"}]}]},{"title":"Week 26: 1.Feeling of hunger","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","spread":"2.69"},{"groupId":"OG001","value":"-0.09","spread":"2.59"}]}]},{"title":"Week 52: 1.Feeling of hunger","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"2.82"},{"groupId":"OG001","value":"0.07","spread":"2.56"}]}]},{"title":"Week 26: 2.Feeling of fullness","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"2.65"},{"groupId":"OG001","value":"0.29","spread":"2.63"}]}]},{"title":"Week 52: 2.Feeling of fullness","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"2.75"},{"groupId":"OG001","value":"0.06","spread":"2.67"}]}]},{"title":"Week 26: 3.Desire to eat sweet foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"3.04"},{"groupId":"OG001","value":"-0.22","spread":"2.95"}]}]},{"title":"Week 52: 3.Desire to eat sweet foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"3.23"},{"groupId":"OG001","value":"-0.18","spread":"2.85"}]}]},{"title":"Week 26: 4.Desire to eat savoury foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"2.99"},{"groupId":"OG001","value":"-0.56","spread":"3.09"}]}]},{"title":"Week 52: 4.Desire to eat savoury foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"3.15"},{"groupId":"OG001","value":"-0.57","spread":"2.93"}]}]},{"title":"Week 26: 5.Feeling of happiness","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"2.24"},{"groupId":"OG001","value":"0.21","spread":"2.31"}]}]},{"title":"Week 52: 5.Feeling of happiness","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"2.61"},{"groupId":"OG001","value":"0.21","spread":"2.36"}]}]},{"title":"Week 26: 6.Feeling of anxiousness","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"2.92"},{"groupId":"OG001","value":"-0.31","spread":"3.22"}]}]},{"title":"Week 52: 6.Feeling of anxiousness","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"3.03"},{"groupId":"OG001","value":"-0.21","spread":"3.02"}]}]},{"title":"Week 26: 7.Feeling of alertness","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"2.68"},{"groupId":"OG001","value":"0.02","spread":"2.57"}]}]},{"title":"Week 52: 7.Feeling of alertness","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"2.73"},{"groupId":"OG001","value":"0.08","spread":"2.63"}]}]},{"title":"Week 26: 8.Feeling of contentment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"2.37"},{"groupId":"OG001","value":"0.22","spread":"2.42"}]}]},{"title":"Week 52: 8.Feeling of contentment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"2.54"},{"groupId":"OG001","value":"0.17","spread":"2.30"}]}]},{"title":"Week 26: 9.Food cravings during 7 days","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"3.25"},{"groupId":"OG001","value":"-0.03","spread":"3.03"}]}]},{"title":"Week 52: 9.Food cravings during 7 days","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"3.23"},{"groupId":"OG001","value":"-0.17","spread":"2.98"}]}]},{"title":"Week 26: 10.Strength of food cravings","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"3.11"},{"groupId":"OG001","value":"-0.18","spread":"2.97"}]}]},{"title":"Week 52: 10.Strength of food cravings","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"3.13"},{"groupId":"OG001","value":"-0.14","spread":"3.01"}]}]},{"title":"Week 26: 11.Difficulty to resist food cravings","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"3.41"},{"groupId":"OG001","value":"-0.35","spread":"3.18"}]}]},{"title":"Week 52: 11.Difficulty to resist food cravings","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"3.26"},{"groupId":"OG001","value":"-0.30","spread":"3.24"}]}]},{"title":"Week 26: 12.Eating in response to food cravings","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"391"},{"groupId":"OG001","value":"396"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"2.94"},{"groupId":"OG001","value":"-0.12","spread":"2.75"}]}]},{"title":"Week 52: 12.Eating in response to food cravings","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"2.97"},{"groupId":"OG001","value":"-0.01","spread":"2.93"}]}]},{"title":"Week 26: 13.Cravings for chocolate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"3.03"},{"groupId":"OG001","value":"-0.26","spread":"3.02"}]}]},{"title":"Week 52: 13.Cravings for chocolate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"3.13"},{"groupId":"OG001","value":"-0.12","spread":"3.00"}]}]},{"title":"Week 26: 14.Cravings for other sweet foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"2.91"},{"groupId":"OG001","value":"-0.36","spread":"2.94"}]}]},{"title":"Week 52: 14.Cravings for other sweet foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"2.90"},{"groupId":"OG001","value":"-0.24","spread":"3.13"}]}]},{"title":"Week 26: 15.Cravings for fruit or fruit juice","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"3.29"},{"groupId":"OG001","value":"0.01","spread":"3.11"}]}]},{"title":"Week 52: 15.Cravings for fruit or fruit juice","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"3.31"},{"groupId":"OG001","value":"-0.15","spread":"3.14"}]}]},{"title":"Week 26: 16.Cravings for dairy foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"3.05"},{"groupId":"OG001","value":"-0.43","spread":"2.88"}]}]},{"title":"Week 52: 16.Cravings for dairy foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"3.11"},{"groupId":"OG001","value":"-0.16","spread":"2.92"}]}]},{"title":"Week 26: 17.Cravings for starchy foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.81","spread":"2.99"},{"groupId":"OG001","value":"-0.59","spread":"2.64"}]}]},{"title":"Week 52: 17.Cravings for starchy foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"3.04"},{"groupId":"OG001","value":"-0.51","spread":"2.99"}]}]},{"title":"Week 26: 18.Cravings for savoury foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"392"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"3.02"},{"groupId":"OG001","value":"-0.56","spread":"2.93"}]}]},{"title":"Week 52: 18.Cravings for savoury foods","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"2.92"},{"groupId":"OG001","value":"-0.50","spread":"3.09"}]}]},{"title":"Week 26: 19.Difficulty to control eating general","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"391"},{"groupId":"OG001","value":"395"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"3.09"},{"groupId":"OG001","value":"-0.36","spread":"2.79"}]}]},{"title":"Week 52: 19.Difficulty to control eating general","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"3.01"},{"groupId":"OG001","value":"-0.27","spread":"2.82"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results are based on the safety analysis set (SAS), which comprised all randomised participants who received at least one dose of trial product.","description":"Serious adverse events and other AEs were based on the on-treatment observation period, i.e., the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication. All-cause mortality were based on the in-trial observation period, i.e., the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.","eventGroups":[{"id":"EG000","title":"Oral Semaglutide 14 mg","description":"Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 14 mg once-daily was reached (i.e. 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to week 52).","deathsNumAffected":0,"deathsNumAtRisk":410,"seriousNumAffected":27,"seriousNumAtRisk":410,"otherNumAffected":128,"otherNumAtRisk":410},{"id":"EG001","title":"Empagliflozin 25 mg","description":"Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was greater than or equal to 60 mL/min/1.73m\\^2 from week 8 to week 52.","deathsNumAffected":1,"deathsNumAtRisk":409,"seriousNumAffected":37,"seriousNumAtRisk":409,"otherNumAffected":44,"otherNumAtRisk":409}],"seriousEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Arteriogram coronary","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":409}]},{"term":"Atrioventricular block second degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Back injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Bundle branch block left","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"CANVAS syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Cardiac failure chronic","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Cerebrovascular disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Cervical dysplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Cholangitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Cholecystectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Clear cell renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Coronary arterial stent insertion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Deep vein thrombosis postoperative","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Ear haemorrhage","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Escherichia urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Head deformity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":409}]},{"term":"Hypocoagulable state","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":409}]},{"term":"Knee arthroplasty","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Lactic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Lacunar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Meningitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Osteochondrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Peptic ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Perichondritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Peripheral vascular disorder","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Pubis fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Rectal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Squamous cell carcinoma of lung","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":409}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Tubo-ovarian abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Uterine prolapse","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":410},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":409}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":410},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":409}]}],"otherEvents":[{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":21,"numAtRisk":410},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":409}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":48,"numAffected":38,"numAtRisk":410},{"groupId":"EG001","numEvents":17,"numAffected":13,"numAtRisk":409}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":410},{"groupId":"EG001","numEvents":23,"numAffected":21,"numAtRisk":409}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":106,"numAffected":81,"numAtRisk":410},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":409}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":30,"numAtRisk":410},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":409}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."},"pointOfContact":{"title":"Clinical Reporting Anchor and Disclosure (1452)","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com","phone":"(+1) 866-867-7178"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-10-02","uploadDate":"2019-10-15T04:18","filename":"Prot_000.pdf","size":3173560},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-10-02","uploadDate":"2019-10-15T04:18","filename":"SAP_001.pdf","size":941131}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000591245","term":"semaglutide"},{"id":"C570240","term":"empagliflozin"}]}},"hasResults":true}